
Intellia Therapeutics (Nasdaq: NTLA), a US biopharma utilizing CRISPR gene editing technology, announced the appointment of Dr Jing Marantz as executive vice president and chief medical officer (CMMO). This appointment is effective October 26, 2026.
Dr Marantz brings over 25 years of experience in the biopharmaceutical industry, with a focus on drug development, including the successful advancement of several rare disease therapies. In her new role, she will oversee Intellia’s translational, development, regulatory, and medical affairs functions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze